The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

Cholangitis is a condition that happens when your bile ducts become inflamed or infected. The bile ducts are thin tubes that ...

近日，消化领域顶级期刊《胃肠病学》（ Gastroenterology ，IF=25.7）以 封面文章 的形式发表了上海交通大学医学院附属仁济医院 马雄教 授课题组最新研究成果。题为 “Gut Microbiota-Derived Butyrate ...

与传统的ERCP相比，胆道子镜辅助的无射线内镜下胆管取石及引流术，即“一步法”内镜下治疗SAC的治疗方式显示了良好的结果，适合SAC的ICU床旁治疗，明显提高患者生存率。因此，该研究为急性重症胆管炎患者提供了一种可行的床旁无射线内镜下治疗的新方法。

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

The global market for primary sclerosing cholangitis (PSC) is on an impressive growth trajectory, with forecasts estimating a ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

Obeticholic acid had been awarded accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...